EGFR and non-small cell lung carcinoma: Over half of the acquired resistance to first-generation EGFR tyrosine kinase inhibitors in NSCLC is due to the appearance of the p.Thr790Met variant of EGFR. Currently, the acquisition of this mutation is no longer such a poor prognosis thanks to a third-generation EGFR TKI called osimertinib.